Reuters reports these are the WHO's first global guidelines on obesity in younger kids, and they put lifestyle changes ahead of weight loss drugs.
Recap by typeshit. Full story at Reuters.
Kalkine Media ties the attention on Lilly to orforglipron's progress, arguing a pill could scale cheaper than injectables and ease supply limits.
Smaller portions could become more common on shelves, with inflation and GLP-1 appetite changes both pushing food makers toward personal packs.
Chokshi notes the sales were 0.4% of Lilly's $23 billion quarter, and that Divi's Labs hasn't announced any role in making the drug.
Oral Wegovy brought in about $850 million in H1 2026 and holds over 80% of new US oral scripts. Lilly says Foundayo volume doubled in a month.
A retrospective look at 65 patients at Leicester's HIV service from 2024 to 2026 turned up an unexpected rate of HIV viral rebound among GLP-1 users.
Medical Xpress reports a small pilot study where people coming off GLP-1 treatment got structured support, with early signs it may help them keep weight off.
Loading…